CClinicalTrials.gg
TerminatedNCT01748162Updated Nov 13, 2017Results posted

Management of Recurrent Croup

A Phase 3 interventional study of Fluticasone and Prednisolone IF needed in Croup, sponsored by University of Michigan. Terminated at 1 site in United States. Open to participants aged 6 Months to 15 Years. Per ClinicalTrials.gov, last updated 2017-11-13.

Sponsored by University of Michigan · Phase 3, Interventional, and Treatment

Phase
Phase 3
Study type
Interventional
Enrollment
10
Allocation
Randomized
Ages
6 Months to 15 Years
Sex
All
01

Study summary

Presently children who experience recurring croup symptoms receive a variety of treatments. This is because it is not clear which treatments may be best. Some children are given inhaled steroids (similar to what children with asthma use). Others are carefully watched and cautioned to avoid potential triggers (certain foods, environmental allergens, etc), and should episodes of croup recur they are treated with a short course of oral steroids. The purpose of this study is to compare two safe and clinically appropriate methods for treating recurrent croup, daily inhaled steroids versus observation with oral steroids on an as needed basis, to see if either is useful in preventing future episodes of croup.

02

Conditions studied

  • Croup

Browse trials for

Keywords

  • croup
  • recurrent croup
  • barky cough
03

Who can participate

Ages eligible
6 Months to 15 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Pediatric population: 6 months to 15 years of age
  • 2 or more episodes of croup in 12 month period

    • croup defined as acute onset inspiratory stridor, barking cough, with respiratory distress.

Exclusion criteria

Exclusion Criteria:

  • Grade 3 or 4 subglottic stenosis
  • Subglottic hemangioma
  • Posterior laryngeal cleft
  • Recurrent respiratory papillomatosis
  • External compression (Innominate artery compression, mediastinal mass, (double aortic arch, etc)
  • Symptoms or signs suggesting another cause of stridor, such as epiglottitis, bacterial tracheitis, or supraglottic foreign body
  • Tracheomalacia/ bronchomalacia severe enough to cause respiratory distress
  • Current steroid therapy for previously diagnosed condition, i.e. reactive airway disease.
  • Other medical conditions necessitating chronic steroid utilization
04

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    Inhaled steroids

    Daily inhaled steroids. Fluticasone 2 puffs inhaled orally twice daily for six months.

    Drug: Fluticasone

  • Active comparator
    Oral control

    Patient and clinician observation with short term oral prednisolone as needed. Offered at 1mg/kg (body weight) daily dosing for symptomatic treatment on as needed basis for three days, but may be modified per managing physician's discretion.

    Drug: Prednisolone IF needed

Interventions

  • DrugFluticasone

    Daily inhaled steroids. Fluticasone 2 puffs inhaled orally twice daily for six months.

  • DrugPrednisolone IF needed
05

What researchers measure

Primary outcomes

  1. Quantity of Recurrent Episodes

    Quantity of recurrent croup episodes experienced over a 1 year period by each participating subject.

    Time frame: 1 year

Secondary outcomes

  1. Severity of Croup Episodes

    Severity of recurrent croup episodes based on Westley Croup scale (0 - 17, where 0 is mildest croup symptoms and 17 is most severe symptoms.)

    Time frame: 1 year

06

Results

Posted Nov 13, 2017

Participant flow

10 participants were recruited and consented and had their initial baseline bronchoscopy, but of the 5 at 1 site, only 1 had an actual croup episode within he first 6 months. Because of decreased recruitment, the study was terminated. The other site's data is not fully available due to unexpected staff turnover and systems failures.

Participant flow — Overall Study
MilestoneInhaled SteroidsOral Control
Started55
Started 6 month initial treatment plan22
Completed 6 month initial treatment00
Started 6 month followup00
Completed00
Not completed55
Withdrew: No additional croup episodes to evaluate22
Withdrew: Participant consented but did not begin01
Withdrew: Reasons not available32

Outcome measures

PrimaryQuantity of Recurrent Episodes

Quantity of recurrent croup episodes experienced over a 1 year period by each participating subject.

Time frame:
1 year

No measurements were reported for this outcome.

SecondarySeverity of Croup Episodes

Severity of recurrent croup episodes based on Westley Croup scale (0 - 17, where 0 is mildest croup symptoms and 17 is most severe symptoms.)

Time frame:
1 year

No measurements were reported for this outcome.

Adverse events

Collected over Six months (because study was terminated based on no participants having additional episodes).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Inhaled Steroids—0/5 (0%)0/5 (0%)
Oral Control—0/5 (0%)0/5 (0%)

Baseline characteristics

Age, Customized
Age, Customized(Participants)Inhaled SteroidsOral ControlTotal
6 months to 15 years5510
Sex: Female, Male
Sex: Female, Male(Participants)Inhaled SteroidsOral ControlTotal
Female022
Male213
Region of Enrollment
Region of Enrollment(Participants)Inhaled SteroidsOral ControlTotal
United States5510
07

Study locations

1 site
  • University of Michigan
    Ann Arbor, Michigan 48109, United States
08

References and documents

09

Registry details

Key details

Study ID
NCT01748162
Lead sponsor
University of Michigan
Responsible party
David Brown (Associate Professor of Otorhinolaryngology, University of Michigan) — Principal investigator
First posted
Dec 12, 2012
Start date
Sep 2012
Primary completion
Jun 2014
Completion
Jun 2014
Results posted
Nov 13, 2017
Last update
Nov 13, 2017

Study contacts

David J Brown, MD
principal investigator · University of Michigan Department of Otolaryngology-Head & Neck Surgery

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion